• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Design Therapeutics Inc.

    4/23/26 4:08:17 PM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DSGN alert in real time by email
    DEFA14A 1 dsgn-defa14a-2026.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

    Filed by the Registrant ☒ Filed by a party other than the Registrant ☐

     

    Check the appropriate box:

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐ Definitive Proxy Statement

    ☒ Definitive Additional Materials

    ☐ Soliciting Material Pursuant to § 240.14a-12

    Design Therapeutics, Inc.

    (Name of Registrant as Specified In Its Charter)

    N/A

    (Name of Person(s) Filing Proxy Statement if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒ No fee required.

    ☐ Fee paid previously with preliminary materials

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11


     

    img71530116_0.jpg

    DESIGN THERAPEUTICS P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! Design Therapeutics, Inc. Annual Meeting of Stockholders Tuesday, June 9, 2026 8:00 AM, Pacific Time Annual Meeting to be held live via the Internet - please visit www.proxydocs.com/DSGN for information. For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/DSGN To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 29, 2026. Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 9, 2026 For Stockholders of record as of April 14, 2026 To order paper materials, use one of the following methods. Internet: www.investorelections.com/DSGN Call: 1-866-648-8133 Email: paper@investorelctins.com * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Go Green! To receive documents via e-mail, simply go to: www.proxydocs.com/DSGN Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. SEE REVERSE FOR FULL AGENDA Copyright © 2026 BetaNXT, Inc. or its affiliates. All Rights Reserved


     

    img71530116_1.jpg

    DESIGN THERAPEUTICS Design Therapeutics, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1 AND 2 PROPOSAL 1. To elect one nominee for Class II director named herein to serve for a three-year term until the 2029 Annual Meeting of Stockholders. 1.01 Simeon George, M.D. 2. To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.


    Get the next $DSGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DSGN

    DatePrice TargetRatingAnalyst
    5/12/2026Overweight
    Cantor Fitzgerald
    3/16/2026$15.00Buy
    Jefferies
    1/7/2026$18.00Outperform
    Oppenheimer
    12/3/2025$14.00Market Perform → Outperform
    Leerink Partners
    12/3/2025$15.00Buy
    Craig Hallum
    11/20/2025$13.00Sector Perform → Outperform
    RBC Capital Mkts
    5/7/2024$6.00 → $12.00Neutral → Overweight
    Piper Sandler
    11/14/2023$42.00 → $6.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $DSGN
    SEC Filings

    View All

    SEC Form 8-K filed by Design Therapeutics Inc.

    8-K - Design Therapeutics, Inc. (0001807120) (Filer)

    5/18/26 7:15:07 AM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Design Therapeutics Inc.

    SCHEDULE 13G/A - Design Therapeutics, Inc. (0001807120) (Subject)

    5/15/26 4:26:52 PM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Design Therapeutics Inc.

    10-Q - Design Therapeutics, Inc. (0001807120) (Filer)

    4/28/26 4:13:37 PM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DSGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

    CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 1:25 p.m. ET in New York. A live webcast of the fireside chat will be available here and in the investors section of the company's website at www.designtx.com.The webcast will be archived for at least 30 days following each presentation. About Design TherapeuticsDesign Therapeutics is a clinical-stage biotechnology company developing a new class

    5/28/26 8:00:00 AM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia

    DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endogenous frataxin mRNA and protein after four weeks of intravenous dosing DT-216P2 generally well-tolerated Data support advancement toward registrational development Management to host conference call and webcast today at 8:00 am ET CARLSBAD, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced positive biomarker and clinical data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich ataxia (FA). DT-216P

    5/18/26 7:00:00 AM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich's Ataxia on Monday, May 18, 2026

    CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich's ataxia (FA) on Monday, May 18, 2026. Management will host a conference call and webcast at 8:00 a.m. ET. A live webcast of the presentation will be available here and in the investors section of the company's website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation. About Design TherapeuticsDesign Therapeutics is a clinical-stage bi

    5/17/26 4:00:00 PM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DSGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Shapiro David

    4 - Design Therapeutics, Inc. (0001807120) (Issuer)

    4/1/26 4:17:20 PM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Shapiro David

    3 - Design Therapeutics, Inc. (0001807120) (Issuer)

    4/1/26 4:11:45 PM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Storgard Chris

    4 - Design Therapeutics, Inc. (0001807120) (Issuer)

    1/5/26 4:14:17 PM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DSGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Schmid John P. bought $99,738 worth of shares (26,965 units at $3.70) (SEC Form 4)

    4 - Design Therapeutics, Inc. (0001807120) (Issuer)

    3/25/24 7:10:26 PM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Berger Heather A. bought $4,866 worth of shares (1,300 units at $3.74) (SEC Form 4)

    4 - Design Therapeutics, Inc. (0001807120) (Issuer)

    3/25/24 7:09:14 PM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lappe Rodney W bought $49,287 worth of shares (21,000 units at $2.35), increasing direct ownership by 19% to 133,024 units (SEC Form 4)

    4 - Design Therapeutics, Inc. (0001807120) (Issuer)

    10/2/23 6:01:58 PM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DSGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Design Therapeutics

    Cantor Fitzgerald initiated coverage of Design Therapeutics with a rating of Overweight

    5/12/26 8:31:09 AM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Design Therapeutics with a new price target

    Jefferies initiated coverage of Design Therapeutics with a rating of Buy and set a new price target of $15.00

    3/16/26 8:40:28 AM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Design Therapeutics with a new price target

    Oppenheimer initiated coverage of Design Therapeutics with a rating of Outperform and set a new price target of $18.00

    1/7/26 9:09:56 AM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DSGN
    Leadership Updates

    Live Leadership Updates

    View All

    Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer

    CARLSBAD, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of Chris M. Storgard, M.D., as Chief Medical Officer (CMO). Dr. Storgard brings over two decades of leadership and hands-on drug development experience, having successfully advanced multiple assets from preclinical stages through global regulatory approvals. "We are thrilled to welcome Chris to our team at this exciting time for Design, as we advance our portfolio of GeneTAC® small molecules toward key clinical milestones," said Pratik Shah, Ph.D., chairperson an

    4/17/25 8:00:00 AM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

    SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

    4/17/25 7:00:00 AM ET
    $ANAB
    $DSGN
    $PSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Business Services

    Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

    Phase 1 Trial of DT-216, a Novel FA GeneTAC™ Molecule, in Patients with Friedreich Ataxia On Track to Begin Soon Preclinical Data Supporting Development of Novel GeneTAC™ Small Molecules for the Treatment of Fuchs Endothelial Corneal Dystrophy (FECD) to be Presented at ARVO 2022 Well-Capitalized with $384.1 Million in Cash and Investments at the End of 2021 to Support Upcoming Milestones CARLSBAD, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced pipeline and business progress and reported fourth quarter and full year 2021 financial results. "This is an e

    3/10/22 4:02:00 PM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DSGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Design Therapeutics Inc.

    SC 13D/A - Design Therapeutics, Inc. (0001807120) (Subject)

    8/13/24 6:53:06 PM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Design Therapeutics Inc. (Amendment)

    SC 13G/A - Design Therapeutics, Inc. (0001807120) (Subject)

    2/14/24 4:58:16 PM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Design Therapeutics Inc. (Amendment)

    SC 13G/A - Design Therapeutics, Inc. (0001807120) (Subject)

    2/14/24 3:01:26 PM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DSGN
    Financials

    Live finance-specific insights

    View All

    Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia

    DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endogenous frataxin mRNA and protein after four weeks of intravenous dosing DT-216P2 generally well-tolerated Data support advancement toward registrational development Management to host conference call and webcast today at 8:00 am ET CARLSBAD, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced positive biomarker and clinical data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich ataxia (FA). DT-216P

    5/18/26 7:00:00 AM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich's Ataxia on Monday, May 18, 2026

    CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich's ataxia (FA) on Monday, May 18, 2026. Management will host a conference call and webcast at 8:00 a.m. ET. A live webcast of the presentation will be available here and in the investors section of the company's website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation. About Design TherapeuticsDesign Therapeutics is a clinical-stage bi

    5/17/26 4:00:00 PM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

    New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025 IND Cleared for DT-168 for Treatment of Fuchs Endothelial Corneal Dystrophy (FECD) with Phase 1 Development to Start in 2024; Observational Study Underway to Confirm Patient Characteristics and Evaluate Potential Endpoints New Program Unveiled for Huntington's Disease (HD) Targeting Reduction of Mutant Huntingtin with a GeneTAC™ Small Molecule Cash and Securities of $281.8 Million at Year-end 2023 Support Five-Year Operating Runway and Advancement of Up to Four Progra

    3/19/24 4:01:00 PM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care